|
J Biol Chem, Vol. 273, Issue 40, 26202-26209, October 2, 1998
The Carboxyl Terminus of Pneumocystis carinii
Glycoprotein A Encodes a Functional Glycosylphosphatidylinositol
Signal Sequence*
Gayle
Guadiz §,
Constantine G.
Haidaris ¶,
Gabriel N.
Maine§, and
Patricia J.
Simpson-Haidaris § **
From the Departments Microbiology and Immunology,
§ Medicine, Vascular Medicine Unit, ¶ Dental Research,
and Pathology and Laboratory Medicine, University of Rochester
School of Medicine and Dentistry, Rochester, New York 14642
 |
ABSTRACT |
Pneumocystis carinii pneumonia is a
hallmark disease associated with AIDS. An abundant glycoprotein, termed
gpA, on the surface of P. carinii is considered an
important factor in host-parasite interactions. The primary structure
of ferret P. carinii gpA contains a carboxyl-terminal
sequence characteristic of a signal for glycosylphosphatidylinositol (GPI) anchors. Here we report the capacity for this gpA carboxyl sequence to direct attachment of a secreted protein, human growth hormone (hGH), to the membranes of COS cells. A control fusion protein
(hGHDAF37) was obtained which, under the direction of the GPI signal
from decay accelerating factor, directs hGH cell surface expression. A
construct (phGH2-1A30) was created similar to hGHDAF37 by fusing hGH to
the putative GPI signal sequence encoded in the terminal 30 residues
from a ferret P. carinii gpA cDNA clone. By indirect
immunofluorescent staining, hGH was detected on the surface of COS
cells transfected with phGH2-1A30; this surface location was confirmed
by confocal laser cytometry. Metabolic labeling with
[3H]ethanolamine and subsequent immunopurification of hGH
from cells transfected with phGH2-1A30 confirmed that a lipid moiety
characteristic of a conventional GPI anchor was linked covalently to
hGH, and cell surface hGH2-1A30 fusion protein was sensitive to
enzymatic cleavage by phosphatidylinositol-phospholipase C. Furthermore, hGH2-1A30 recombinant protein cofractionated with
5'-nucleotidase, a classical GPI-anchored membrane marker. Together,
these results indicate that the carboxyl-terminal residues of ferret
P. carinii gpA constitute a biologically functional GPI
consensus domain, thus providing a potential mechanism for antigenic
variation of P. carinii gpA during P. carinii
pneumonia.
 |
INTRODUCTION |
Immunocompromised hosts, such as those suffering from AIDS,
cancer, malnutrition, and genetic immunodeficiencies, are susceptible to pneumonitis caused by the opportunistic pathogen Pneumocystis carinii. The pathogenesis of the infection is elusive, largely because of the lack of a continuous in vitro culture system
and no knowledge of its reservoir in nature (1, 2). Thus animal models,
particularly severe combined immunodeficient (SCID) mice and
steroid-treated ferrets and rats, are used to isolate the organism and
to study P. carinii pneumonia (1, 3, 4). Interestingly, the
transmission of P. carinii from one host to another is
restricted to within the same species, and P. carinii organisms isolated from different host species exhibit host
species-specific karyotypes (5), genotypes (6-8), and antigens
(9-11).
Much insight on the biology and pathogenicity of P. carinii
has stemmed from studies of one antigen, glycoprotein A
(gpA).1 Also termed major
surface glycoprotein, gpA is an immunodominant surface antigen thought
to facilitate attachment of P. carinii to type I alveolar
epithelial cells (1, 12). P. carinii remains extracellular
throughout P. carinii pneumonia, and the organism binds to
several host adhesive glycoproteins and surfactant apoproteins via gpA
(13-16). Passive immunoprophylaxis using anti-gpA monoclonal antibodies (mAbs) partially protects against P. carinii
pneumonia; therefore, gpA may be a target of the humoral response in
the prevention or recovery from infection (17, 18). Therapeutic approaches using anti-gpA antibodies are complicated, however, by the
dramatic differences in gpA phenotypes among organisms isolated from
various host species, as well as from a single host species. Although
many gpA-specific mAbs have been characterized, only one mAb (5E12)
recognizes a carbohydrate-containing epitope on gpA shared by P. carinii isolates from all host species studied (18). GpA genes are
scattered in clusters throughout the P. carinii genome in
highly polymorphic isoforms detected even within the same individual
host (1, 6-8, 19). It remains inconclusive whether infection arises
from multiple P. carinii organisms, each expressing single
gpA isoforms, or from a single organism expressing polymorphic genes
(20). Despite this ambiguity, the known characteristics of P. carinii gpA indicate some form of antigenic variation.
Although the life cycle of P. carinii is not fully defined,
several developmental forms have been identified. These include pleiomorphic trophozoites, thin walled precysts, and thick walled mature cysts containing up to eight intracystic bodies that, upon excystation, result in daughter trophozoites to repeat the cycle (2).
All of these life cycle stages show surface staining for gpA using
specific mAbs and polyclonal antibodies (pAbs) (2, 21). However, the
mode of attachment of gpA to the P. carinii surface remains
undetermined. The primary structure of gpA lacks a traditional
hydrophobic transmembrane domain for insertion of the protein into a
lipid bilayer (6-8). The absence of such a mechanism is consistent
with the P. carinii cyst wall structure that, like yeast
cell walls, consists of an inner plasma membrane surrounded by a thick
layer of -glucan (22, 23). Another mechanism for surface antigen
attachment commonly employed by eukaryotes, including protozoa and
yeast, is glycosylphosphatidylinositol (GPI) anchorage mediated by a
characteristic carboxyl-terminal sequence. This sequence consists of a
stretch of hydrophobic amino acids preceded by a short string of
hydrophilic residues. Upstream of this domain is a trio of amino acids
with small side groups that represent the cleavage and attachment site
for GPI. One of the most well characterized GPI-anchored proteins is
the variant surface antigen (VSG) of Trypanosoma brucei.
Cleavage via GPI-phospholipase C (GPI-PLC) and anchorage of a new
isoform variant of VSG provide an efficient mechanism for antigenic
variation and immune evasion (24-26).
Analyses of gpA cDNA clones isolated from ferret P. carinii revealed a carboxyl-terminal sequence with domains
characteristic of GPI-anchored proteins (19). Deduced amino acid
sequences from rat (8) and human (6) P. carinii gpA also
display conserved regions indicative of signal sequences for GPI
attachment. Although several standard methods exist for determining GPI
anchorage, such procedures are hindered by the crude sources of
P. carinii organisms, which must be isolated from infected
animal lungs. These preparations inevitably contain host phospholipases
and GPI-anchored proteins. To circumvent this limitation, we used a
molecular approach to determine whether the 3'-terminus of a ferret gpA
mediates attachment of a secreted protein, human growth hormone (hGH),
to the surface of transfected COS cells via a GPI anchor.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
Radionuclides, [3H]ethanolamine, and
[35S]cysteine + [35S]methionine were
purchased from Amersham Pharmacia Biotech and NEN Life Science
Products, respectively. Goat anti-hGH pAb and expression vector
phGHDAF37 (27) containing hGH with a 37-amino acid carboxyl-terminal sequence containing the decay accelerating factor (DAF) GPI signal sequence were a kind gift from Genentech (South San Francisco, CA).
Goat anti-hGH pAb and rabbit anti-hGH pAb (Dako, Carpinteria, CA) were
used for immunopurification and indirect immunofluorescent staining.
Fluorescein isothiocyanate-conjugated anti-goat IgG antibodies were
obtained from Miles-Yeda (Israel), and BODIPY-conjugated goat
anti-rabbit IgG was purchased from Molecular Probes Inc. (Eugene, OR).
Protein G-Sepharose (Sigma) beads were used for immunopurification of
metabolically labeled growth hormone. All tissue culture flasks, cell
culture media, and media supplements were purchased from Life
Technologies unless otherwise indicated, as were all DNA- and
RNA-modifying enzymes. Kits were used per the manufacturers'
instructions: Wizard (Promega), Sephaglas, (Amersham Pharmacia
Biotech), and Exsite (Stratagene).
Isolation and Characterization of Ferret gpA cDNA Clone
2-1A--
A cDNA clone bank in gt11 was constructed previously
using mRNA isolated from ferret lungs heavily infected with
P. carinii (8). Phage expressing gpA were isolated and
mapped on the ferret gpA gene composite constructed previously by
Wright et al. (19) using gt11 primers coupled with ferret
P. carinii gpA-specific primers (Table
I) in the polymerase chain reaction (PCR)
as described (19). One clone, designated 2-1A, was subcloned from
gt11 into the EcoRI site of pGEM7Zf( ) (Promega) for
further analysis. DNA sequencing was performed using the Perkin-Elmer
Abiprism Dye Terminator method at the Nucleic Acid Core Facility at the
University of Rochester. The nucleotide sequence of clone 2-1A is
deposited in GenBank under accession number AF035226.
View this table:
[in this window]
[in a new window]
|
Table I
Primer sequences used for analysis of gpA clone 2-1A and construction
of hGH2-1A30
FgpA 307-10AS 07 sense primer was used previously for analyzing
ferret-derived gpA sequence, and the FgpA-GPI antisense primer was
designed from gpA sequence determined in the same study (19). Primers
were designed to construct the 2-1A30 fragment and phGHm1 mutant,
adding XhoI and HindIII recognition sites at the
5' -termini. The native sequence corresponding to positions on the
respective templates is underlined (last four primers).
|
|
PCR and Site-directed Mutagenesis--
Site-directed mutagenesis
was conducted using gpA and hGH-specific oligonucleotides with
XhoI and HindIII site adapters to facilitate
cloning the 30 carboxyl-terminal amino acids containing the putative
GPI signal of 2-1A-gpA and to replace the 37 amino acids of the GPI
signal of DAF in phGHDAF37 (Table I). The amplification reaction to
obtain mutagenized 2-1A was performed for 30 cycles of 94 °C for 2 min, 50 °C for 2 min, and 72 °C for 4 min. The PCR product was
purified (Promega Wizard kit) and then digested with XhoI
and HindIII overnight at room temperature. The phGHDAF37 construct was mutagenized using the Stratagene Exsite procedure (1 cycle of 94 °C for 4 min, 50 °C for 2 min, and 72 °C for 2 min; 12 cycles of 94 °C for 1 min, 56 °C for 2 min, and 72 °C for 1 min; 1 cycle of 72 °C for 5 min). After amplification, tubes were cooled to 37 °C, and DpnI and PfuI
polymerase were added and then incubated for 30 min at 37 °C and 30 min at 72 °C. PCR products were purified after agarose gel isolation
using Sephaglas, and then the purified DNA was phosphorylated with T4
DNA kinase before ligation with T4 DNA ligase. The resulting constructs
were designated phGH2-1A30 and phGHm1 as shown in Fig.
1.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic of cloning strategy for
construction of phGH2-1A30. The DAF37 sequence was deleted from
hGHDAF37 by PCR site-directed mutagenesis using flanking primers. This
generated a mutant (phGHm1) containing unique HindIII and
XhoI recognition sites just downstream of hGH. The plasmid
was ligated after DpnI and PfuI treatment,
phosphorylation, and purification. A 3'-region of ferret gpA clone 2-1A
containing the putative GPI signal sequence was amplified by PCR using
primers that also inserted XhoI and HindIII
recognition sequences (step 2), thus generating the fragment 2-1A30
encoding the 30 terminal residues DEEEEVVPSGGRKWLPSLSIVIVGVVVALV and
the stop codon. Both phGHm1 and 2-1A30 were digested simultaneously
with XhoI and HindIII for forced cloning and then
ligated to generate the construct hGH2-1A30 (step 3). Symbols:
octagon, stop codon; triangle, cytomegalovirus
promoter/enhancer; hexagon, SV40 polyadenylation signal;
rectangles, cloning sites; dashed arrows,
oligomer encoding restriction enzyme recognition sites.
|
|
Transfection into COS Cells--
COS cells were transfected with
plasmids containing the inserts hGHDAF37, hGH2-1A30, and the hGHm1
mutant lacking the DAF GPI signal sequence. Cells were plated onto
glass coverslips, six-well cluster plates, or T-25 flasks in complete
medium consisting of Dulbecco's modified Eagle's medium/medium F-12
(DMEM/F-12) with 1 × L-glutamine, 1×
penicillin-streptomycin, 10% fetal bovine serum (Intergen, Purchase,
NY). The transfection was performed using LipofectAMINE reagent
complexed with 1.0-10 µg of plasmid DNA for 45 min, during which
time the cells were starved in serum-free DMEM/F-12. The medium was
then replaced with serum-free medium containing the DNA-LipofectAMINE
complexes. Transfection proceeded for 5 h, and then an equivalent
amount of DMEM/F-12 and 20% fetal bovine serum medium was added.
Transfection continued for a total duration of 24-48 h. For metabolic
labeling studies, transfections were carried out for 24 h;
transfection medium was then replaced with complete medium containing
[3H]ethanolamine at 50 µCi/ml or
[35S]Met/Cys at 40 µCi/ml and radiolabeled for 16 h. Immunoprecipitation was performed using goat anti-hGH pAbs and
protein G-Sepharose beads (28). For immunofluorescent staining, cells
were washed, fixed in 3.7% formaldehyde, then probed with goat
anti-hGH antibodies and stained with fluorescein
isothiocyanate-conjugated anti-goat IgG antibodies (Miles-Yeda) as
described previously (28).
PI-PLC Cleavage--
Transfected COS cells were cultured in
six-well culture plates and treated with recombinant PI-PLC from
Bacillus thuringiensis (Oxford Glycosystems, Rosedale, NY)
to demonstrate cleavage of the GPI phosphatidylinositol moiety. After a
24-h transfection with phGHDAF37, phGH2-1A30, or phGHm1, cells were
radiolabeled continuously for 16 h with [35S]Met/Cys
in complete medium. Conditioned medium was removed and then pooled with
three subsequent washes of Hanks' balanced salt solution. PI-PLC (1 unit/ml) in buffer (RPMI 1640 supplemented with 0.2% bovine serum
albumin, 50 µM -mercaptoethanol, 10 mM HEPES, 0.1% sodium azide) was added directly to the wells (29); control cells received buffer only. Cells were incubated in a 37 °C
CO2 incubator for 1 h. Supernatants were collected and
pooled with three subsequent Hanks' buffered salt solution washes,
cells were lysed, and then whole cell lysates and supernatants plus rinses were immunopurified to detect cell-associated or released hGH,
respectively.
Confocal Scanning Laser Cytometry (CSLC)--
To determine
whether the recombinant fusion proteins encoded by phGHDAF37 and
phGH2-1A30 were directed to the plasma membrane, transfected COS cells
were analyzed by CSLC. Cells cultured on glass coverslips were
transfected with 2.5 µg of plasmid DNA for 40 h, fixed with
formalin, and permeabilized with Triton X-100. The treated cells were
incubated with rabbit anti-hGH pAb (8 µg/ml) followed by incubation
with BODIPY-conjugated goat anti-rabbit IgG (1:200). The cellular
locale of fluorescence was determined by CSLC using a Meridian Ultima
Adherent Cell Analysis System and its accompanying Data Analysis System
Master Program V3.32 (Meridian Instruments, Inc., Okemos, MI). All
samples were examined under oil immersion using a 100 × objective
and scanned using an identical set of parameters so that results from
different cells could be compared. Samples were excited by a 488 nm
argon laser line, and emitted fluorescence was detected by a
photomultiplier tube with an upper limit of 575 nm. Data were collected
from serial, 1 µm-thick optical sections along the Z-axis
(vertical axis) at steps of 0.5 µm. From the data points collected,
false color digitized images of scanned cells were generated and then
converted to gray scale for photographic reproduction.
Cell Fractionation and 5'-Nucleotidase Activity Assay--
To
confirm localization of hGH to the plasma membranes of transfected
cells, whole cell lysates from 2 × T-75-cm2 flasks
were fractionated using Percoll (Amersham Pharmacia Biotech). COS cells
were transfected with 75 µg of phGH2-1A30 for 40-48 h, then lysed
and pooled in 2.4 ml of lysis buffer (0.25 M sucrose, 3 mM imidazole, 10 mM leupeptin, 200 units/ml
aprotinin, and 5 mM EDTA in 10 mM Tris-HCl, pH
8.0) (30), and disrupted in a glass hand-held homogenizer (Wheaton,
Millville, NJ) with 10 strokes. The cell suspension was centrifuged at
1,500 × g for 10 min. Supernatants were removed for
further centrifugation, and pellets were resuspended in 200 µl of
phosphate-buffered saline and frozen at 20 °C. Percoll (2.6 ml)
was added to each supernatant, mixed gently by inversion, and then
transferred to 13 × 51-mm Beckman ultracentrifuge tubes. The
mixture was centrifuged in a Beckman ultracentrifuge using a SW 55Ti
rotor at 70,000 × g for 15 min at 5 °C. Five
fractions of 830 µl were removed from the top to bottom of each tube
and then diluted in phosphate-buffered saline to 5 ml. Samples were centrifuged at 200,000 × g for 45 min at 5 °C to
form a Percoll pellet. The top 4 ml was removed, and the remaining 1 ml
was transferred to new tubes for further centrifugation at 200,000 × g for 45 min (30). Supernatants were removed carefully,
saving the last 200 µl for analysis by gel electrophoresis and
enzymatic activity measurement.
Equal volumes of each sample were analyzed, reduced on a 12.5%
polyacrylamide gel, and then transferred onto nitrocellulose filters. A
standard Western blot procedure utilizing chemiluminescence reagent was
performed (NEN Life Science Products) using rabbit anti-hGH pAb
followed by anti-rabbit IgG conjugated to horseradish peroxidase.
Growth hormone was detected by exposure to autoradiographic film, and
bands were quantitated by densitometric scanning using the NIH Image
1.59 program. In parallel, the enzymatic activity of a GPI-anchored
plasma membrane marker, 5'-nucleotidase, was determined using a reagent
kit from Sigma Diagnostics. The data were plotted as relative
densitometric units of hGH and 5'-nucleotidase activity detected in
each fraction.
 |
RESULTS |
A gt11 cDNA library was constructed previously from
mRNA isolated from P. carinii-infected ferret lungs (8).
After induction of gene expression with isopropyl
1-thio- -D-galactopyranoside and screening with
polyclonal anti-gpA, four positive plaques were isolated and mapped by
PCR on the ferret gpA gene composite constructed previously by Wright
et al. (19). One clone, designated 2-1A, was selected for
further analysis because of its size (>1.9 kilobase pairs) and
relative position at the 3'-end of the gpA gene. PCR amplification of
the gpA 2-1A plasmid template with M13 universal forward and FgpA-GPI
antisense primers (Table I) indicated that the cDNA clone included
sequences encoding the putative GPI attachment site. Nucleotide
sequencing confirmed that clone 2-1A encodes a stretch of amino acids
characteristic of a signal for GPI attachment (Table
II).
View this table:
[in this window]
[in a new window]
|
Table II
Comparison of ferret P. carinii gpA putative GPI carboxyl-terminal
sequence with known GPI carboxyl terminal sequences
The GPI consensus signal is composed of a stretch of hydrophobic amino
acids at the carboxyl terminus (underlined residues) preceded by a core
of hydrophilic amino acids (parentheses). Immediately upstream of the
hydrophilic amino acids, three residues with small side groups
(boldfaced type) represent the cleavage-attachment site for the lipid
anchor (32, 45). Covalent amide linkage formation between the protein
and its GPI anchor requires cleaving the 3'-translated sequence
downstream of the first small amino acid (boldfaced, space in sequence)
of the signal sequence. An ethanolamine molecule and glycan core
comprise the conserved regions of the GPI molecule. The glycolipids
that mediate attachment to cell membranes consist of varying structures
of glycosylated inositol moieties, which secure the protein onto the
plasma membrane (31, 32).
|
|
Direct analysis of P. carinii gpA attachment is problematic
without an in vitro culture system. We utilized a eukaryotic
expression system to determine whether the extreme 3'-sequence of
cDNA clone 2-1A encoded amino acids that could direct attachment of
hGH to the COS cell membranes. A construct (phGHDAF37) was obtained
consisting of hGH fused to a sequence with the well characterized GPI
signal sequence from DAF (27). PCR site-directed mutagenesis was
designed to delete the DAF37 sequence and to add a set of unique
restriction sites (XhoI and HindIII) for forced
cloning into this region downstream of hGH (Fig. 1); the resulting
plasmid was designated phGHm1. DNA encoding the putative GPI signal
sequence from gpA clone 2-1A, designated 2-1A30, was also isolated by
PCR using primers that added the corresponding unique cloning sites
XhoI and HindIII. The 2-1A30 sequence encoding
the signal for GPI attachment of hGH was cloned into phGHm1. The
constructs phGHDAF37, phGHm1, and phGH2-1A30 were expressed transiently
in COS cells, and cell surface hGH expression was assessed by indirect
immunofluorescent staining of nonpermeabilized cells. Cells transfected
with phGHDAF37 expressed striking levels of hGH on the cell membrane,
as detected with a specific pAb to hGH (Fig.
2A). Transfection with phGHm1, lacking the DAF signal sequence for GPI attachment, did not result in
detectable cellular hGH (Fig. 2C), nor was any detectable on control cells (Fig. 2D). Importantly, transfection with
phGH2-1A30 resulted in membrane hGH expression (Fig. 2B)
comparable to that seen with phGHDAF37 (Fig. 2A), displaying
intense cell-associated fluorescence.

View larger version (66K):
[in this window]
[in a new window]
|
Fig. 2.
Indirect immunofluorescent staining of
transfected COS cells. COS cells were transfected with 2.5 µg of
phGHDAF37 (panel A), phGH2-1A30 (panel B), phGHm1
(panel C), and control, no plasmid DNA (panel D).
Cells were cultured on glass coverslips to >50% confluence, then
transfections proceeded for 24-48 h. Cells were washed, fixed, and
immunostained for hGH expression. The bar in panel
D represents 20 µm.
|
|
A standard feature present on all GPI-anchored proteins is an
ethanolamine molecule bridging GPI to the carboxyl terminus of the
protein through an amide linkage (31, 32). Hence, copurification of
this moiety with a cell-associated hGH strongly indicates formation of
a GPI lipid anchor mediating membrane attachment. COS cells were
transfected with the constructs hGHDAF37, hGHm1, and hGH2-1A30 for
24 h, and then culture medium was replaced with fresh medium containing [3H]ethanolamine. Cell lysates were
immunopurified with antibodies to hGH, and samples were analyzed by
SDS-polyacrylamide gel electrophoresis and fluorography. Control cells
that underwent the same transfection conditions, but without plasmid
DNA, did not express cellular hGH linked to
[3H]ethanolamine (Fig. 3,
No DNA). Similarly, expression of cellular hGH was not
evident in hGHm1 transfectants (Fig. 3, hGHm1).
Immunopurification with anti-hGH pAb from phGHDAF37-transfected cells
isolated a protein migrating to the expected molecular mass of hGH at
~24 kDa (Fig. 3, hGHDAF37). A similar pattern of hGH bands
was also isolated from the lysate of phGH2-1A30-transfected cells (Fig. 3, hGH2-1A30), demonstrating that cell-associated hGH
contains ethanolamine, indicative of a GPI anchor.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 3.
[3H]Ethanolamine radiolabeling
of COS cell transfectants. COS cells were transfected with 10 µg
of phGHDAF37 (first lane from left),
phGH2-1A30 (second lane), or phGHm1
(third lane) for 24 h, then radiolabeled
with 50 µCi/ml [3H]ethanolamine in complete medium for
16 h. The fourth lane is a control of cells not
transfected but subjected to the same experimental conditions. Cells
were washed in phosphate-buffered saline before lysis, and lysates were
immunoprecipitated with goat anti-hGH pAb conjugated to protein
G-Sepharose beads. Immunopurified samples were reduced and resolved in
12.5% polyacrylamide gels by SDS-electrophoresis and then analyzed by
fluorography. Molecular mass markers (Mr) are,
from top to bottom, in kDa: 200, 97, 68, 46, 30, 21, and 14. The solid arrow represents the migratory
position of hGHDAF37; the dashed arrow represents the
position of migration of the hGH2-1A fusion protein.
|
|
The lipid moieties of GPI-anchored proteins render them susceptible to
cleavage by exogenous, as well as endogenous, phospholipases (31, 32).
PI-PLC is the most widely studied and utilized of the phospholipases in
analyzing GPI attachment (31, 33). PI-PLC purified from bacterial
extracts of Staphylococcus aureus and B. thuringiensis effectively cleave many eukaryotic GPI anchors, although some are resistant because of modified inositol molecules (33). To apply this method of GPI detection and characterization to our
system, we transfected COS cells with phGHDAF37, phGH2-1A30, and phGHm1
and then treated the cells with PI-PLC derived from B. thuringiensis. Enzyme treatment released a detectable portion of
the expressed hGH from cells into the supernatants of hGHDAF37 and
hGH2-1A30 transfectants (Fig. 4).

View larger version (117K):
[in this window]
[in a new window]
|
Fig. 4.
PI-PLC cleavage of hGH. COS cells
transfected with 5 µg of phGHDAF37 or phGH2-1A30 were treated with
PI-PLC to determine whether membrane-bound hGH was susceptible to
enzymatic cleavage. Samples of phGH2-1A30 transfectants represent
5-fold more cells than phGHDAF37 transfectants. hGH released by PI-PLC
treatment and that remaining cell-associated were immunopurified and
analyzed by electrophoresis on 12.5% acrylamide gels and fluorography.
Each sample is designated with the transfection construct, (+) or ( )
PI-PLC treatment, and either supernatant (sup) or cell
lysate (cells). Molecular mass markers
(Mr) are the same as indicated in Fig. 3.
Open arrows designate GPI-linked hGH; closed
arrows represent PI-PLC -cleaved hGH.
|
|
Conventional fluorescence microscopy clearly demonstrated that COS
cells transfected with phGH2-1A30 expressed hGH at levels comparable to
cells transfected with phGHDAF37; the pattern of cell surface
fluorescence (Fig. 2), together with the biochemical analyses (Figs. 3
and 4), suggested localization on the cell membrane. To confirm that
the recombinant fusion proteins encoded by phGHDAF37 and phGH2-1A30
were directed to the plasma membrane, transfected COS cells were
analyzed by CSLC. This method allows visualization of optical sections
of cells and permits precise localization of surface antigens. Cells
transfected with each of the plasmids were stained for the expression
of hGH using specific antibody and a fluorochrome-conjugated secondary
antibody. Serial, 1-µm optical sections of transfected cells were
scanned by CSLC, and the fluorescent signal was converted to gray
scale, with white areas representing the most intense fluorescence.
Serial scans of transfected cells indicated that the bulk of the
immunostaining is localized to the cell membrane, demonstrating that
the replacement of the DAF GPI signal sequence (Fig.
5A) with the P. carinii gpA carboxyl-terminal peptide (Fig. 5B)
resulted in functional anchoring of hGH on the COS cell surface.

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 5.
Surface localization of hGH2-1A30 by CSLC of
transfected COS cells. To localize hGH expression specifically in
transfected COS cells, CSLC was performed. Cells cultured to ~50%
confluence on glass coverslips were transfected with 2.5 µg of
phGHDAF37 (panel A) or phGH2-1A30 (panel B).
Monolayers were fixed, permeabilized, and stained with rabbit anti-hGH
pAb followed by BODIPY-conjugated goat anti-rabbit IgG pAb. The value
in the upper right corner of each panel
represents the position of the optical section in µm relative to the
initiation of scanning. Sequential sections starting from the cells'
basolateral surfaces demonstrate the specific location of fluorescence,
which is indicative of surface localization of hGH.
|
|
To confirm localization of the fusion protein hGH2-1A30 to the plasma
membrane, transfected cells were fractionated by ultracentrifugation in
a Percoll gradient. The enzymatic activity of 5'-nucleotidase, a
GPI-anchored protein used as a standard marker of plasma membranes (34), was measured for comparison with the relative amounts of growth
hormone in each fraction. The results are presented in Fig.
6 as relative densitometric units for hGH
or units/liter of 5'-nucleotidase activity. The bulk of 5'-nucleotidase
activity (>30 units/liter) and growth hormone was detected in the cell pellet (not shown), consistent with common techniques of isolating nuclei and plasma membrane sheets using this technique (35). 5'-Nucleotidase enzymatic activity, indicative of plasma membrane isolation, cofractionated with hGH in Fraction 2 (2.3 units/liter) and
Fraction 3 (1.1 units/liter) (Fig. 6), whereas Fraction 1 likely
corresponded to intracellular hGH. Recombinant hGHDAF37 also copurified
in cell membrane fractions containing 5'-nucleotidase activity (not
shown). These results demonstrate that the cellular fractions
containing growth hormone indeed consisted of plasma membranes,
verifying surface expression of hGH directed by the P. carinii gpA-GPI anchor.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Cell fractionation and determination of
5'-nucleotidase (5'-NTase) activity. To ascertain that
growth hormone was on the plasma membrane of phGH2-1A30 transfectants,
cell lysates were fractionated in a Percoll gradient and then analyzed
by Western blotting for detection of growth hormone. Enzymatic activity
of a plasma membrane marker, 5'-nucleotidase, was also quantitated in
the same samples using a kinetic assay (Sigma Diagnostics). Relative
units of growth hormone, determined by densitometric scanning, were
plotted on the same graph with the 5'-nucleotidase activity measured in
units/liter.
|
|
 |
DISCUSSION |
A significant area of study in P. carinii pathogenesis
has concentrated on characterizing gpA and understanding its impact on
establishing disease. Recent studies have provided substantial evidence
that gpA molecules isolated from different hosts exhibit genotypic,
phenotypic, and antigenic polymorphism (6-8). Furthermore, individual
infected hosts harbor organisms that express multiple divergent
isoforms of gpA encoded by genes dispersed in clusters throughout the
genome, suggesting that heterogeneity in this immunodominant antigen
may be a considerable factor in the organism's mode of survival (19,
36). Despite the marked differences in gpA gene expression, gpA
homologs demonstrate several conserved properties, such as surface
localization, molecular mass, a common carbohydrate epitope, and
cysteine-rich domains (10, 11, 37). Wright et al. (19) also
reported a novel property of ferret P. carinii gpA, namely
the expression of a carboxyl-terminal domain conserved among eukaryotic
GPI-anchored proteins. In our study, we sought to determine whether
this putative GPI signal sequence could direct expression and membrane
attachment of a secretory protein via a GPI moiety. Indeed, the
presumed GPI signal sequence of an expressed gpA cDNA clone
mediated hGH membrane attachment comparably to that of the well
established mammalian DAF signal (27, 38). We determined conclusively
by confocal scanning laser cytometry and cofractionation with another
GPI-anchored membrane marker, 5'-nucleotidase, that hGH2-1A30
transfectants, as well as hGHDAF37 controls, expressed membrane-bound
hGH. The likelihood that the carboxyl-terminal sequence of gpA is an
efficient signal for GPI attachment in P. carinii is
supported by the results of this study.
The molecular approach described in our study arose from the difficulty
in analyzing P. carinii without an in vitro
system to culture clonal populations. By utilizing a marker, such as a
secreted protein or a reporter enzyme, one can ascertain definitively whether GPI membrane attachment is directed by a particular primary structure. For example, the mating factors a- and -agglutinin of
Saccharomyces cerevisiae are processed through a
GPI-anchored intermediate before cross-linking into the -glucan of
the cell wall (39-42). A fusion protein consisting of the signal
sequence of yeast invertase, -galactosidase, and the
carboxyl-terminal half of -agglutinin to provide the GPI addition
signal resulted in expression of the enzyme on the cell surface (43).
The construct obtained from Genentech, hGHDAF37, encodes a fusion
protein that, despite a secretory signal sequence, anchors hGH to the
mammalian cell membrane via the DAF carboxyl-terminal GPI sequence
(27). However, fusions made between hGH and the GPI attachment sequence of T. brucei VSG failed to become membrane-bound (38).
Mutational analyses identified the cleavage-attachment site between the
first two residues of a trio of amino acids in the VSG GPI signal as responsible for the inability to anchor hGH. Various amino acid substitutions in this position restored the ability of the VSG sequence
to mediate GPI-anchored hGH membrane expression (38). The upstream
amino acid of this trio, termed , remains attached to the anchored
protein after cleavage. A hierarchy of residues in the position
facilitates anchorage in the order of: serine, asparagine, glycine,
alanine, aspartate, cysteine, leucine, valine, and all others (44, 45).
Another critical property appears to be the +2 position, which
requires a residue with a small side chain. The native VSG attachment
site, consisting of aspartate ( ), serine ( +1), and serine
( +2), is apparently less suitable using these criteria (44). From
their studies, Moran and Caras (38) hypothesized that protozoan and
mammalian cells exhibit similar but not identical prerequisites for GPI
attachment. Such a disparity between lower eukaryotes and mammalian
requirements was not evident in our study because the P. carinii carboxyl sequence encoded by phGH2-1A30 directed hGH
membrane attachment. In fact, several factors strongly support our
theory that gpA is GPI-linked. The putative cleavage-attachment site in
clone 2-1A represents the optimal amino acids at the and +2
positions, respectively, serine and glycine (44). The overall
characteristics for the carboxyl-terminal GPI signal sequence,
particularly the hydrophobic tail, appear conserved among ferret (19),
rat (8), mouse (46), and human (6) sources of P. carinii
(Table III). Lipid domains, such as
cholesterol, have been postulated to play a role in regulating the
distribution of GPI-anchored proteins (47, 48). Because cholesterol is
the major sterol synthesized by P. carinii, a similar
regulation is possible (49). The phospholipid profile of P. carinii includes the presence of phosphatidylethanolamine and
phosphatidylinositol (50-52), consistent with components of a GPI
anchor (31, 32).
View this table:
[in this window]
[in a new window]
|
Table III
Comparison of potential GPI signal sequences on gpA of P. carinii
derived from different host species
The GPI consensus signal is denoted as described in the legend to Table
II.
|
|
Based on our evidence that the carboxyl terminus of gpA can function as
a signal for GPI anchor addition in mammalian cells, it is tempting to
speculate that at least a portion of the gpA molecules is anchored to
the surface of P. carinii organisms in a similar manner. If
so, it would have interesting implications for the biology of the
organism and the pathogenesis of P. carinii pneumonia. By
analogy to the African trypanosome T. brucei, which sheds
its existing VSG coat via GPI-PLC cleavage during antigenic variation
(24-26), P. carinii may use a similar mechanism to shed existing gpA isoforms so that they may be replaced by a different isoform. Furthermore, it is known that VSG expression in T. brucei is regulated by duplicative transposition of a VSG gene
from a storage copy elsewhere in the genome into a telomeric expression site. There is substantial evidence that gpA expression by P. carinii is regulated in a similar manner (36, 53), in which a
genomic storage copy of gpA recombines into a telomeric expression site. Although it is unknown whether more than one isoform of gpA is
expressed by a single organism, a population of P. carinii from an individual infected lung expresses multiple isoforms of gpA,
and the large number of copies of gpA genes in the genome assures the
capacity for extensive heterogeneity in the antigenic repertoire (1, 8,
19, 53, 54). An endogenous PI-PLC in P. carinii could
facilitate the replacement of gpA isoforms on the organism surface. If
such a mechanism of antigenic variation exists in P. carinii, it is not as efficient as that seen in T. brucei. Unlike the African trypanosome, P. carinii is
not an overt pathogen, and any capacity for antigenic variation of gpA
is dealt with adequately by the immunocompetent host. However, as the
immune system wanes during immunodeficiency states, a capacity for
variation in its immunodominant surface antigen may give the
opportunist P. carinii the edge it needs to establish
infection in the lung.
The structure of the P. carinii cyst wall strongly mirrors
the composition of fungal cell walls, particularly S. cerevisiae and Candida albicans (22, 23, 55).
GPI-anchored proteins are abundant on and within the thick -glucan
layer encompassing the plasma membrane of S. cerevisiae and
C. albicans, and treatment with glucanase liberates these
structural components (36, 55-59). Several studies of the S. cerevisiae mating factor -agglutinin have suggested that the
protein is anchored to the plasma membrane via GPI before traversing
the -glucan layer for exposure on the cell wall surface (41). The
model is supported by evidence of -agglutinin intermediates that, in
their transport to the cell wall, may cross-link with -glucan
components (40, 41). Mutations to dolichyl phosphoryl mannose
synthetase and phosphomannomutase, which prevent GPI synthesis, are
lethal, suggesting a vital function for GPI-anchored proteins in fungal
cell wall biosynthesis and cell survival (56). Other fungal
GPI-anchored surface proteins include S. cerevisiae
GGP1/GAS1 (58) and C. albicans PHR1 (60), proteins thought
to be involved in cellular morphogenesis. Because GPI-anchored
glycoproteins may be important in yeast cell wall composition,
function, and morphology, it is possible that GPI-anchored gpA
expressed on the different developmental forms during the life cycle of
P. carinii may relate to morphogenesis as well. The major
life forms of P. carinii are the trophozoite and cyst, with
an intermediate precystic stage (2). Our laboratory demonstrated previously that most gpA transcription occurs in the actively replicating forms of P. carinii, the trophic and precystic
forms, whereas the majority of mature cysts express minimal gpA
mRNA (61). Cyst walls thicken during transition from the trophic and precystic forms (2); therefore, P. carinii morphogenesis may be related to the expression of GPI-linked gpA and its ability to
promote attachment to lung epithelium and adhesiveness in alveolar exudate. GpA is abundant on the plasma membrane in the trophozoite (61), and a reported outer surface membrane on P. carinii
cysts (22) suggests that a GPI anchor could mediate surface attachment of gpA on cysts. Alternatively, the GPI anchor may be part of an
intermediate step, as described for -agglutinin S. cerevisiae (40), and mature cyst walls may not contain detectable
GPI-anchored gpA. In support of a model consisting of an intermediate
GPI attachment, gpA is not readily released from cysts without
stringent glucanase treatment (1, 23). Although these mechanisms remain
elusive before the development of an in vitro cultivation
system, the demonstration of a functional GPI signal sequence on gpA
heralds compelling new implications for its role in P. carinii physiology and pathogenesis.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Irene Caras and Genentech for
graciously providing phGHDAF37 expression vector and polyclonal
anti-human growth hormone antiserum and Dr. Karen Norris from the
University of Pittsburgh School of Medicine for helpful suggestions
regarding experimental design. From the University of Rochester we
thank Dr. Mary-Anne Courtney for assisting with nucleotide sequencing and Drs. Francis Gigliotti and Terry Wright for critical reading and
helpful comments regarding the manuscript.
 |
FOOTNOTES |
*
This work was supported by Public Health Service Grants
HL50615, HL49610, and AI07362 from the National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Vascular Medicine Unit,
Dept. of Medicine, P.O. Box 610, University of Rochester, 601 Elmwood
Ave., Rochester, NY 14642. Tel.: 716-275-8267; Fax: 716-473-4314;
E-mail: pj_simpsonhaidaris{at}urmc.rochester.edu.
The abbreviations used are:
gpA, glycoprotein A; CSLC, confocal scanning laser cytometry; DAF, decay accelerating
factor; GPI, glycosylphosphatidylinositol; hGH, human growth hormone; mAb, monoclonal antibody; pAb, polyclonal antibody; PCR, polymerase
chain reaction; PI, phosphatidylinositol, PLC, phospholipase C; VSG, variant surface glycoprotein; BODIPY, 4,4-difluoro-4-bora-3a,4a,diaza-s-indacene-3-propionic
acid.
 |
REFERENCES |
-
Cushion, M. T.,
Harmsen, A.,
Matsumoto, Y.,
Stringer, J. R.,
Wakefield, A. E.,
and Yamada, M.
(1994)
J. Med. Vet. Mycol.
32,
217-228[Medline]
[Order article via Infotrieve]
-
Hopkin, J. M.
(1991)
in
Pneumocystis carinii. (Hopkin, J. M., ed), pp. 1-27, Oxford University Press, New York
-
Armstrong, M. Y. K.,
and Cushion, M. T.
(1994)
in
Pneumocystis carinii Pneumonia (Walzer, P. D., ed), pp. 189-222, Marcel Dekker, New York
-
Chen, W.,
Mills, J. W.,
and Harmsen, A. G.
(1992)
Int. J. Exp. Pathol.
73,
709-720[Medline]
[Order article via Infotrieve]
-
Hong, S.-T.,
Steele, S. E.,
Cushion, M. T.,
Walzer, P. D.,
Stringer, S. L.,
and Stringer, J. R.
(1990)
J. Clin. Microbiol.
28,
1785-1795[Abstract/Free Full Text]
-
Garbe, T. R.,
and Stringer, J. R.
(1994)
Infect. Immun.
62,
3092-3101[Abstract/Free Full Text]
-
Haidaris, P. J.,
Wright, T. W.,
Gigliotti, F.,
and Haidaris, C. G.
(1992)
J. Infect. Dis.
166,
1113-1123[Medline]
[Order article via Infotrieve]
-
Kovacs, J. A.,
Powell, F.,
Edman, J. C.,
Lundgren, B.,
Martinez, A.,
Drew, B.,
and Angus, C. W.
(1993)
J. Biol. Chem.
268,
6034-6040[Abstract/Free Full Text]
-
Bauer, N. L.,
Paulsrud, J. R.,
Bartlett, M. S.,
Smith, J. W.,
and Wilde, C. A.
(1993)
Infect. Immun.
61,
1315-1319[Abstract/Free Full Text]
-
Gigliotti, F.
(1992)
J. Infect. Dis.
165,
329-336[Medline]
[Order article via Infotrieve]
-
Walzer, P. D.,
and Rutledge, M. E.
(1980)
J. Infect. Dis.
142,
449[Medline]
[Order article via Infotrieve]
-
Yoneda, K.,
and Walzer, P. D.
(1980)
Infect. Immun.
29,
692-703[Abstract/Free Full Text]
-
Limper, A. H.,
Pottratz, S. T.,
and Martin, W. J.
(1991)
J. Lab. Clin. Med.
118,
492-499[Medline]
[Order article via Infotrieve]
-
Limper, A. H.,
Standing, J. E.,
Hoffman, O. A.,
Castro, M.,
and Neese, L. W.
(1993)
Infect. Immun.
61,
4302-4309[Abstract/Free Full Text]
-
Pottratz, S. T.,
Paulsrud, J.,
Smith, J. S.,
and Martin, W. J.
(1991)
J. Clin. Invest.
88,
403-407
-
Zimmerman, P. E.,
Voelker, D. R.,
McCormack, F. X.,
Paulsrud, J. R.,
and Martin, W. J.
(1992)
J. Clin. Invest.
89,
143-149
-
Fisher, D. J.,
Gigliotti, F.,
Zauderer, M.,
and Harmsen, A. G.
(1991)
Infect. Immun.
59,
3372-3376[Abstract/Free Full Text]
-
Gigliotti, F.,
and Hughes, W. T.
(1988)
J. Clin. Invest.
81,
1666-1668
-
Wright, T. W.,
Bissoondial, T. Y.,
Haidaris, C. G.,
Gigliotti, F.,
and Simpson-Haidaris, P. J.
(1995)
DNA Res.
2,
77-88[Abstract]
-
Gigliotti, F.,
Garvy, B. A.,
and Harmsen, A. G.
(1996)
Infect. Immun.
64,
1892-1899[Abstract]
-
Gigliotti, F.,
Stokes, D. C.,
Cheatham, A. B.,
Davis, D. S.,
and Hughes, W. T.
(1986)
J. Infect. Dis.
154,
315-322[Medline]
[Order article via Infotrieve]
-
De Stefano, J. A.,
Cushion, M. T.,
Sleight, R. G.,
and Walzer, P. D.
(1990)
J. Protozool.
37,
428-435[Medline]
[Order article via Infotrieve]
-
Matsumoto, Y.,
Matsuda, S.,
and Tegoshi, T.
(1989)
J. Protozool.
36,
21S-22S[Medline]
[Order article via Infotrieve]
-
Bangs, J. D.,
Hereld, D.,
Krakow, J. L.,
Hart, G. W.,
and Englund, P. T.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
3207-3211[Abstract/Free Full Text]
-
Ferguson, M. A. J.,
Homans, S. W.,
Dwek, R. A.,
and Rademacher, T. W.
(1988)
Science
239,
753-759[Abstract/Free Full Text]
-
Hereld, D.,
Krakow, J. L.,
Bangs, J. D.,
Hart, G. W.,
and Englund, P. T.
(1986)
J. Biol. Chem.
261,
13813-13819[Abstract/Free Full Text]
-
Caras, I. W.,
Weddell, G. N.,
and Williams, S. R.
(1989)
J. Cell Biol.
108,
1387-1396[Abstract/Free Full Text]
-
Guadiz, G.,
Sporn, L. A.,
and Simpson-Haidaris, P. J.
(1997)
Blood
90,
2644-2653[Abstract/Free Full Text]
-
Bergelson, J. M.,
Chan, M.,
Solomon, K. R.,
St. John, N. F.,
Lin, H.,
and Finberg, R. W.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
6245-6248[Abstract/Free Full Text]
-
Cezanne, L.,
Navarro, L.,
and Tocanne, J.-F.
(1992)
Biochim. Biophys. Acta
1112,
205-214[Medline]
[Order article via Infotrieve]
-
Cross, G. A. M.
(1990)
Annu. Rev. Cell Biol.
6,
1-39[CrossRef]
-
Englund, P. T.
(1993)
Annu. Rev. Biochem.
62,
121-138[CrossRef][Medline]
[Order article via Infotrieve]
-
Low, M. G.,
Stiernberg, J.,
Waneck, G. L.,
Flavell, R. A.,
and Kincade, P. W.
(1988)
J. Immunol. Methods
113,
101-111[CrossRef][Medline]
[Order article via Infotrieve]
-
Aronson, N.,
and Touster, O.
(1974)
Methods Enzymol.
31,
90-102[CrossRef][Medline]
[Order article via Infotrieve]
-
Spector, D. L.,
Goldman, R. D.,
and Leinwald, L. A.
(1998)
Cells: A Laboratory Manual, Vol. 1, pp. 34.1-34.9, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
-
Sunkin, S. M.,
and Stringer, J. R.
(1996)
Mol. Microbiol.
19,
283-295[CrossRef][Medline]
[Order article via Infotrieve]
-
Wright, T. W.,
Simpson-Haidaris, P. J.,
Gigliotti, F.,
Harmsen, A. G.,
and Haidaris, C. G.
(1994)
Infect. Immun.
62,
1513-1519[Abstract/Free Full Text]
-
Moran, P.,
and Caras, I. W.
(1994)
J. Cell Biol.
125,
333-343[Abstract/Free Full Text]
-
Conzelmann, A.,
Fankhauser, C.,
Puoti, A.,
and Desponds, C.
(1991)
Cell Biol. Int. Rep.
15,
863-873[CrossRef][Medline]
[Order article via Infotrieve]
-
Lu, C.-F.,
Montjin, R. C.,
Brown, J. L.,
Klis, F.,
Kurjan, J.,
Bussey, H.,
and Lipke, P. N.
(1995)
J. Cell Biol.
128,
333-340[Abstract/Free Full Text]
-
Lu, C.-F.,
Kurjan, J.,
and Lipke, P. N.
(1994)
Mol. Cell. Biol.
14,
4825-4833[Abstract/Free Full Text]
-
Wojciechowicz, D.,
Lu, C.-F.,
Kurjan, J.,
and Lipke, P. N.
(1993)
Mol. Cell. Biol.
13,
2554-2563[Abstract/Free Full Text]
-
Schreuder, M. P.,
Brekelmans, S.,
van den Ende, H.,
and Klis, F. M.
(1993)
Yeast
9,
399-409[CrossRef][Medline]
[Order article via Infotrieve]
-
Rosse, W. F.,
and Ware, R. E.
(1995)
Blood
86,
3277-3286[Free Full Text]
-
Kodukula, K.,
Gerber, S. D.,
Amthauer, R.,
Brink, L.,
and Udenfriend, S.
(1993)
J. Cell Biol.
120,
657-664[Abstract/Free Full Text]
-
Haidaris, C. G.,
Medzhiradsky, O. F.,
Gigliotti, F.,
and Simpson-Haidaris, P. J.
(1998)
DNA Res.
5,
77-85[Abstract]
-
Rothberg, K. G.,
Ying, Y.-S.,
Kamen, B. A.,
and Anderson, R. G. W.
(1990)
J. Cell Biol.
111,
2931-2938[Abstract/Free Full Text]
-
Webster, P.,
Joiner, K.,
and Andrews, N.
(1991)
Cell Biol. Int. Rep.
15,
799-813[CrossRef][Medline]
[Order article via Infotrieve]
-
Florin-Christensen, M.,
Florin-Christensen, J.,
Wu, Y.- P.,
Zhou, L.,
Gupta, A.,
Rudney, H.,
and Kaneshiro, E. S.
(1994)
Biochem. Biophys. Res. Commun.
198,
236-242[CrossRef][Medline]
[Order article via Infotrieve]
-
Guo, Z.,
and Kaneshiro, E. S.
(1995)
Infect. Immun.
63,
1286-1290[Abstract]
-
Kaneshiro, E. S.,
and Sleight, R. G.
(1994)
in
Pneumocystis carinii Pneumonia (Walzer, P. D., ed), pp. 45-71, Marcel Dekker, New York
-
Pesanti, E. L.
(1987)
Infect. Immun.
55,
736-741[Abstract/Free Full Text]
-
Wada, M.,
Sunkin, S. M.,
Stringer, J. R.,
and Nakamura, Y.
(1995)
J. Infect. Dis.
171,
1563-1568[Medline]
[Order article via Infotrieve]
-
Wada, M.,
and Nakamura, Y.
(1996)
DNA Res.
3,
55-64[Abstract]
-
Kapteyn, J. C.,
Montjin, R. C.,
Dijkgraaf, G. J. P.,
and Klis, F. M.
(1994)
Eur. J. Cell Biol.
65,
402-407[Medline]
[Order article via Infotrieve]
-
de Nobel, H.,
and Lipke, P. N.
(1994)
Trends Cell Biol.
4,
42-45[CrossRef][Medline]
[Order article via Infotrieve]
-
Muller, G.,
Schubert, K.,
Fiedler, F.,
and Bandlow, W.
(1992)
J. Biol. Chem.
267,
25337-25346[Abstract/Free Full Text]
-
Vossen, J. H.,
Ram, A. F. J.,
and Klis, F. M.
(1995)
Biochim. Biophys. Acta
1243,
549-555[Medline]
[Order article via Infotrieve]
-
Nuoffer, C.,
Jeno, P.,
Conzelmann, A.,
and Riezman, H.
(1991)
Mol. Cell Biol.
11,
27-37[Abstract/Free Full Text]
-
Saporito-Irwin, S. M.,
Birse, C. E.,
Sypherd, P. S.,
and Fonzi, W. A.
(1995)
Mol. Cell. Biol.
15,
601-613[Abstract]
-
Haidaris, P. J.,
Wright, T. W.,
Gigliotti, F.,
Fallon, M. A.,
Whitbeck, A. A.,
and Haidaris, C. G.
(1993)
Mol. Microbiol.
7,
647-656[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Fankhauser and P. Maser
Identification of GPI anchor attachment signals by a Kohonen self-organizing map
Bioinformatics,
May 1, 2005;
21(9):
1846 - 1852.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Kottom, C. F. Thomas Jr., and A. H. Limper
Characterization of Pneumocystis carinii PHR1, a pH-Regulated Gene Important for Cell Wall Integrity
J. Bacteriol.,
December 1, 2001;
183(23):
6740 - 6745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Palmer and A. E. Wakefield
Functional Glycosylphosphatidylinositol Anchor Signal Sequences in the Pneumocystis carinii PRT1 Protease Family
Am. J. Respir. Cell Mol. Biol.,
October 1, 2001;
25(4):
466 - 473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Stringer and S. P. Keely
Genetics of Surface Antigen Expression in Pneumocystis carinii
Infect. Immun.,
February 1, 2001;
69(2):
627 - 639.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Odrljin, C. G. Haidaris, N. B. Lerner, and P. J. Simpson-Haidaris
Integrin {alpha}v{beta}3-Mediated Endocytosis of Immobilized Fibrinogen by A549 Lung Alveolar Epithelial Cells
Am. J. Respir. Cell Mol. Biol.,
January 1, 2001;
24(1):
12 - 21.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
B. Eisenhaber, P. Bork, and F. Eisenhaber
Post-translational GPI lipid anchor modification of proteins in kingdoms of life: analysis of protein sequence data from complete genomes
Protein Eng. Des. Sel.,
January 1, 2001;
14(1):
17 - 25.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|